- Why Cryoport
- Who We Serve
- About Us
- News & Events
- Investor Relations
- Contact Us
Are your advanced therapy supply chains ready for this year’s 4G/LTE data management transition?
A leap forward in standardizing the regenerative medicine supply chain
As cell and gene therapies are rapidly moving beyond clinical trials and into commercial markets, the safe and effective delivery of these life-saving treatments needs to be a priority for advanced therapy developers. Can the same supply chain solutions, processes, and systems used during the clinical trial phases handle the increased volume of a commercial therapy on a global basis? The significant growth and rapid innovation of the regenerative medicine industry increases the complexities and risks associated with transporting therapies when shipping in a non-compliant environment. This places unique pressure on supply chain providers to standardize their processes and become far more agile, all while maintaining operational excellence in a zero-failure environment.
Cryoport Systems’ highly anticipated Global Supply Chain Centers have been operational for a few months, and customers continue to move biopharmaceutical materials into our Houston, Texas and Morris Plains, New Jersey facilities in order to mitigate risks.
Our new Global Supply Chain Centers were established in direct response to client requests, and represent the initial stages of a global network that offers specialized logistics support and BioServices solutions. Therapy developers require dependable partners with suitable facilities to help them manage their valuable materials, such as therapeutic products and manufacturing raw materials.